NBIX | tickerfilter.com

Fundamental analysis

51%

Profitability 68%

Dept financing 9%

Liquidity 51%

Performance 44%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-16.85%

1 Month

-10.00%

3 Months

-7.02%

6 Months

-5.64%

1 Year

17.22%

2 Year

23.00%

Key data

Stock price

$127.06

P/E Ratio

37.82

DAY RANGE

N/A - $129.71

EPS

$3.28

52 WEEK RANGE

$103.63 - $157.98

52 WEEK CHANGE

$0.15

MARKET CAP

12.830 B

YIELD

N/A

SHARES OUTSTANDING

100.976 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

10/31/2024

BETA

0.39

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,409,924

AVERAGE 30 VOLUME

$955,525

Company detail

CEO: Kevin Gorman
Region: US
Website: http://www.neurocrine.com/
Employees: 1,252
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders

NBIX - Neurocrine Biosciences, Inc.